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CHAPTER 1 
 RESEARCH OBJECTIVES 
1. Introduction 
The ultimate purpose of this project was to create a modified stem cell line which could 
enhance nerve regeneration following peripheral nerve trauma. Specifically, this work was 
focused upon answering two questions. First, could we chemically transdifferentiate 
genetically modified mesenchymal stem cells to resemble a Schwann cell-like state? A 
protocol for the chemical transdifferentiation of MSCs was validated and well tested in the 
Sakaguchi lab, but no one had ever attempted to chemically transdifferentiate BDNF hyper-
secreting MSCs. Second, if we succeeded in creating BDNF hyper-secreting 
transdifferentiated MSCs (BDNF tMSCs), would levels of BDNF secretion be affected, and, 
more importantly, would the secreted BDNF still be biologically active? We hypothesized that 
BDNF tMSCs would still resemble a Schwann cell like phenotype and be able to produce the 
same or lower amounts of biologically active BDNF when compared to their undifferentiated 
and GFP control counterparts. Generated data relied largely on the use of 
immunocytochemistry to quantify the percentage of cells expressing Schwann cell markers. 
BDNF secretion was quantified by ELISA and bioactivity was tested using the PC12-trkB 
assay. This study was an important first step in characterizing these BDNF tMSCs by in vitro 
assays and was essentially a proof of concept study to show that genetically modified MSCs 
could still be chemically transdifferentiated. As a next step, we hope to seed these BDNF 
tMSCs within a polymeric conduit transplant used in a rat sciatic nerve transection model to 
test the ability of these cells to aid in nerve regeneration in vivo.  
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2. Summary 
The main objectives of this research project are: 
1. Chemical transdifferentiation of BDNF MSCs into SC-like phenotypic cells 
2. Assessment of SC marker expression levels via immunocytochemistry 
3. Measurement of BDNF secretion pre-and post transdifferentiation via ELISA 
4. Assessment of BDNF bioactivity via PC12-trkB cell assay 
3. Organization of thesis 
Chapter 2 is a literature review, which will provide the background context for 
understanding the importance of peripheral nerve regeneration therapies and the key role that 
Schwann cells play in this process. The review also discusses the benefits of cell transplants 
and how, in particular, autologous mesenchymal stem cells offer many advantages such as 
genetic modification.  The chapter continues with a focus on the ways that unmodified and 
modified MSCs have been used in clinical trials and what nervous system diseases may benefit 
from their use. Finally, the review ends with a discussion of current and future 
transdifferentiation methods and trends.  
Chapter 3 is adapted from a manuscript we have submitted for publication, detailing 
the effects of chemical transdifferentiation on BDNF hyper-secreting MSCs. Finally, chapter 
4 is a summary of important results and conclusions drawn from this dissertation.  
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CHAPTER 2 
 A REVIEW OF MESENCHYMA STEM CELL THERAPIES IN THE CONTEXT OF 
PERIPHERAL NERVE REGENERATION 
1. Introduction 
In order to understand the true therapeutic potential for transdifferentiated brain derived 
neurotrophic factor (BDNF) mesenchymal stem cells (MSCs), it is important to put the 
research into a clinical perspective. MSCs which have been altered to resemble and act like 
Schwann cells have key beneficial properties within the context of peripheral nerve trauma 
such as enhancing neuron survival and improving return to function. The prevalence of 
peripheral nerve trauma remains surprisingly high and current treatment options have several 
pitfalls. Newer remedies, such as cell transplants, are in high demand because the traditional 
gold standard requires the sacrifice of a healthy nerve. In particular, Schwann cells are essential 
to Wallerian degeneration (1,2,3) and nerve regeneration (4,5,6,7) and are excellent transplant 
candidates (5,6,7,8). However, Schwann cells are difficult to culture in vitro and are a mature 
cell line, thus requiring a healthy nerve for harvest (9). Studies within the last twenty years 
have instead searched for easily harvested cells, capable of transdifferentiating into a Schwann 
cell phenotype and found that mesenchymal stem cells are capable of expressing Schwann cell 
markers, promoting neural tissue survival, and improving return to function in peripheral nerve 
injuries (10, 11, 12, 13, 14). In addition to mimicking Schwann cells, MSCs have their own 
benefits, such as secreting neurotrophic factors and serving as a vehicle for genetic 
modification (15, 16, 17, 18, 19). Our project has focused on genetically modified MSCs which 
can hyper-secrete the growth factor BDNF and have the ability to provide neuroprotection and 
increased neurite outgrowth. Our lab has used these cells in rat studies of glaucoma models 
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(20), however, we have never tested them in models of peripheral nerve injury, which is one 
aim of this study.  
 Another goal of the study was to determine whether or not these BDNF MSCs could be 
transdifferentiated to resemble Schwann-like cells and further characterize them with in vitro 
assays in order to add to the growing pool of pre-clinical data necessary for future human trials. 
Unmodified mesenchymal stem cells have been used in many clinical trials for nervous system 
disorders and even genetically modified MSCs made to hyper-secrete growth factors have been 
tested. However, transdifferentiated MSCs have yet to be tested as a treatment for human 
disorders and require much more extensive in vitro studies to ensure their safety and efficacy. 
A key part of the in vitro studies is determining the best method of transdifferentiation. 
Methods include the use of co-culture or direct transplantation, small molecule/chemical 
transdifferentiation, or overexpression of a master gene via genetic modification. In particular, 
our lab has focused on the method of chemical transdifferentiation as it is a relatively rapid 
process, does not require a viral vector, and has a high success rate of cell conversion. Our 
overall goal was to test and characterize the ability of BDNF MSCs to undergo 
transdifferentiation and explore their relevance as a therapeutic treatment option for peripheral 
nerve injuries. The following chapter will provide the reader with a more in-depth review of 
current treatment options and their pitfalls; the use of cell transplants, especially Schwann cells 
and MSCs; and, finally, the use of transdifferentiation to create Schwann-like cells from MSCs 
and their benefits to peripheral nerve regeneration.  
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2. Peripheral nerve injuries- Causes & Prevalence 
Peripheral nerve injuries (PNIs) may be caused by a variety of etiologies including trauma, 
metabolic disorders such as Diabetes mellitus, or iatrogenic surgical complications.  The most 
common cause of PNIs are trauma during which nerves may suffer from traction, ischemia, 
crushing, or penetrating wounds (21). Other less common causes may include thermal, electric 
shock, radiation, or vibrational injuries (22,23).  The majority of incidents are stretch-related 
injuries, especially in motor vehicle accidents (24), while lacerations by knife, glass, saw, or 
long bone fractures are only 30% of serious nerve injuries (21).  In a study of 1,167 cases of 
peripheral nerve injury, 5.7% of cases were related to sports (25).  In a retrospective study by 
Kouyoumdjian (2006), 456 cases of PNIs showed upper limb injuries to be the most common, 
with the ulnar nerve most often injured (26). Again, these injuries were most often due to motor 
vehicle accidents, particularly motorcycle crashes.  In addition to affecting civilians, PNIs can 
commonly occur in a combative setting, where nerve injuries are commonly caused by 
shrapnel or blast injury from bombs or improvised explosive devices (27).  
After suffering from a peripheral nerve injury, a patient’s prognosis depends on the type of 
functional injury they have experienced. At the anatomic level, nerve injury can be divided 
into neurapraxia, axonotmesis, and neurotmesis according to Sir Herbert Seddon (28). In 
neurapraxia, the nerve remains intact but can no longer transmit impulses. Neurapraxia is 
typically due to segmental demyelination and is the mildest form of nerve injury. Distally, the 
nerve conducts normally but there is impaired conduction across the lesion due to the focal 
demyelination.  Axons are typically anatomically intact but nonfunctional, which renders a 
body part paralyzed. There is sensory and motor loss due to demyelination but no Wallerian 
degeneration occurs. Clinically, muscle atrophy does not develop. Recovery time is typically 
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rapid and ranges from hours to a few months. Full function is usually expected without any 
sort of intervention by 12 weeks (21).  
In axonotmesis, the axon is damaged but most of the surrounding connective tissue is 
intact. Wallerian degeneration does occur. Axonotmesis is usually seen in stretch or crush 
injuries. Recovery and reinnervation depends upon the distance from nerve to muscle and the 
degree of internal axonal disorganization.  
  In neurotmesis, the nerve trunk is severed and most of the connective tissue is lost or 
distorted. Neuroetmesis occurs with massive trauma, nerve avulsions, and sharp, cutting injury. 
There is loss of nerve trunk continuity and reinnervation typically does not occur. Without 
surgical intervention, the prognosis is poor. Recovery from this sort of trauma when there is 
significant axon loss and stromal disruption is usually prolonged and incomplete (29).  
When suffering from neurotmesis or axonotmesis, injuries can cause total or partial 
loss of motor, sensory, or even autonomic function. When left to repair itself, the peripheral 
nervous system can attempt one of three mechanisms: reinnervation by axonal regeneration, 
reinnervation by collateral branching of uninjured surrounding axons, or remodeling of the 
nervous system circuitry; however, left to only these mechanisms, a full functional recovery is 
often not achieved (29, 30, 31). Failure can be attributed to three problems: First, axons stop 
elongating and result in neuroma formation. Second, axon sprouts innervate more than one 
peripheral nerve branch and cause weak or contradicting muscle movements. Third, 
regeneration into the wrong nerve can occur if, for example, a sensory axon grows into a motor 
nerve or vice versa (32).    
It is important to understand that while the peripheral nervous system retains the ability 
to reconstruct itself, only 60% of patients suffering from a PNI regain useful function (32). The 
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occurrence of postparalytic syndromes such as paresis, synkinesis, and dysreflexia are common 
(33). Additionally, patients can experience chronic neuropathic pain, health care issues, and 
long periods of sick leave (34, 35).  
Due to the high incidence of unsatisfactory return to function, further improvements in 
peripheral nerve repair and regeneration have become an area of much interest. Today, PNIs 
have become the focus of new innovations which revolve around many different scientific 
disciplines. The following section will focus on the two most common areas of clinical 
treatment: surgery and transplantation. Other disciplines involved such as biomaterial sciences, 
physical therapy, and pharmacotherapy are outside of the realm of this review.  
2.1 Current Treatment Options for PNIs 
The most common medical treatments rely largely on reconstructive microsurgery. 
Although nerve reconstruction has been attempted for centuries, techniques have improved 
drastically within the past few decades (36).  Procedural options include nerve autografts, 
neurolysis, nerve transfers, and direct suture (end to end neurorrhaphy) (37). The nerve 
transfer method has seen widespread application in recent years and is used in severe nerve 
trauma, including brachial plexis avulsions (38, 39).  
Although advances in microsurgical techniques have plateaued, a few interesting 
technological advances have occurred within the past ten years. For example, the use of glue 
rather than suture has been tried in animal models, and results indicate that glue may be equal 
or even superior to epi and perineural microsuturing (40, 41).  Another area of advancement 
is robotics assisted surgery. Results from experimental studies are encouraging and robot 
technologies may be favored by nerve surgeons in the future (42, 43).  
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Microsurgical treatment alone has relatively low success rates, which is why 
transplantation is the approach drawing the most interest in regenerative medicine (37). The 
current “gold standard” includes transplantation of an autologous nerve segment which has 
been harvested from another healthy, less important nerve. The procedure was first developed 
by Millesi (1981) (44) and later deemed the standard of care (36).  Although autograft is the 
“gold standard” the harvesting of another healthy nerve represents obvious limitations, which 
is why veins are sometimes used as an alternative (45). Although vein autografts may lead to 
satisfactory return of sensation, comparable to nerve grafting, they are only useful for short 
distances as longer veins tend to collapse (46).  
In addition to nerve and vein transplants, skeletal muscle used as guiding fibers has also 
been tried with relatively good success. Various studies have shown that muscle conduits may 
potentially bridge peripheral nerve defects (47) and that grafts may even gain some functional 
recovery (48,49,50). 
Apart from tissue transplants, cell transplants are a large area of research. Glial cells, 
specifically, Schwan cells, are a common cell type studied, as well as mesenchymal stem cells. 
The purpose and clinical studies of each cell type will be further discussed in sections 4- 6. 
The following section will explain the process of nerve breakdown and regeneration following 
a traumatic nerve injury and the essential role that Schwann cells play.  
3. Wallerian degeneration 
After damage to a peripheral nerve, a complex system of molecular and cellular events take 
place in order for nerve regeneration to begin. In 1850, August Waller first described Wallerian 
degeneration which is composed of degeneration in the distal nerve stump, with elongation 
and regeneration occurring in the proximal nerve stump (Fig.1) (1,51).  
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Soon after a PNI, Schwann cells in the distal nerve rapidly initiate detachment of their 
myelin sheaths (52).  The surrounding myelin and axonal tissue begin to break down. Within 
hours of injury, histological changes have occurred as neurotubules and neurofilaments 
become disarrayed (53). Within 24 hours of injury, Schwann cells are stimulated by proteins 
released from the disintegrating axons (54), and later, by macrophage cytokines, to proliferate. 
The Schwann cells exhibit an increased mitotic rate as well as nuclear and cytoplasmic 
enlargement and divide rapidly to form daughter cells (53). These daughter cells produce 
cytokines and trophic factors which assist in degeneration and repair (55).  During this time, 
local macrophages (Mast cells) interact with the Schwann cells to remove degenerated axonal 
and myelin debris. Schwann cells and macrophages work together to phagocytose and clear 
the site of injury. By 36-48 hours, myelin disintegration is quite advanced (53).  The 
elimination of myelin sheaths is important as it clears certain growth inhibitory factors such as 
myelin-associated glycoproteins (56).  At the same time that the distal nerve is degenerating, 
the nerve cell body is undergoing a process known as chromatolysis. Within 6 hours of injury, 
the nucleus of the nerve cell body migrates to the periphery of the cells and the rough 
endoplasmic reticulum (Nissl bodies) break up and disperse (57, 58).  In this state, the neuron 
increases RNA synthesis and cellular protein content, and reduces DNA repression, in order to 
increase synthesis of growth-associated proteins and membrane structural components (59).  
Within two days, Schwann cell daughter cells have undergone rearrangement into a 
structure known as Bünger bands (60). These bands act as a guidance skeleton for regenerating 
axon sprouts. Within a week, factors produced by Schwann cells and injured axons leads to 
recruitment of hematogenous monocytes (61).  The new macrophages continue to clear debris 
and produce factors which facilitate Schwann cell migration (55).  
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After weeks to months, axon sprouts begin to form, each with a specialized growth cone at 
the tip which contains multiple filopodia. These filopodia adhere to the basal lamina of the 
Schwan cells within the Bünger bands, which serve as a guide toward potential new targets of 
innervation. Both physical and chemotactic guidance from the Schwann cells are important in 
directing advancement of the growth cone (62, 63). Individual filopodia respond to 
environmental alterations in calcium (64) and different filopodia can react independently via 
local changes to actin metabolism (65).  Once contacted by regenerative sprouts, Schwann 
cells re-differentiate, express myelin mRNAs, and begin the process of remyelating and 
ensheathing fresh axons (21).  If axonal sprouts are able to cross the injury site and contact a 
new peripheral target, then reinnervation may occur. The regeneration and repair phase may 
last for many months and is not always successful. Regenerating axons may enter surrounding 
tissue instead of the target organ or may enter into the incorrect endoneurial tube, failing to 
reinnervate the correct target. After nerve injury and repair, the conduction velocity of 
regenerated axons, their diameter, and their excitability remain below previous levels for a 
long time (67,68).   
In addition to the complex cellular response, PNIs induce the release of many neurotrophic 
factors and cytokines in order to create a favorable environment for axon regrowth. These 
polypeptides assure that the regenerating axons are growing towards the distal nerve stump 
and stimulate axonal sprouting. The following section will review the role of neuronal growth 
factors, particularly brain derived neurotrophic factor, during Wallerian degeneration. 
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4.   The importance of neurotrophic factors during peripheral nerve regeneration  
In response to a peripheral nerve injury, many neurotrophic factors are upregulated. These 
molecules may be classified either as neurotrophic factors or neuropoietic cytokines (69). This 
review will discuss only the neurotrophic factors and will be focused primarily on the role of 
BDNF.  
 
Figure 1. Wallerian degeneration and chromatolysis followed by regeneration. Adapated from 
(66).  
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Neurotrophic factors are vital to neurite outgrowth during embryonic development, 
maintain adult neurons, and aid in regeneration following a PNI (32). The specific 
neurotrophins involved in regeneration include NGF, BDNF, and neurotrophins 3,4, & 5. 
Several growth factors are also released, including glial cell-derived neurotrophic factor, 
fibroblast growth factors, insulin-like growth factors, neuregulins, and neuropeptides (galanin, 
vasoactive intestinal peptide, etc) (70,71).  All neurotrophic factors are believed to be 
synthesized in target organs and then delivered via retrograde transport to the neuronal soma 
(72, 73). The neurotrophin members (NGF, BDNF, NT-3/4/5) share a common low-affinity 
receptor p75 (74) to which they all bind equally. It is thought that p75 interacts with the 
tropomyosin receptor kinases (Trk) to assist in transport of neurotrophins within the neuronal 
terminals (75). Each neurotrophin has a specific high affinity receptor: trkA for NGF, trkB is 
specific for BDNF, and NT-4/5, and NT-3 bind to trkC (76).  Every trk receptor is located in a 
discreet population of primary sensory neurons (77,78) and trkB and C are also present in 
spinal motoneurons (79). The following section will focus on the trkB receptor and the various 
roles that BDNF plays in neuronal regeneration.  
4.1 Promotion of neuron survival 
Activation of each neurotrophin is dependent on the type of neuron damage (motor, 
sensory, or autonomic). BDNF, in particular, is upregulated in motor neurons, as is its receptor, 
TrkB, for 48 hours following an axotomy lesion (80). During this time, BDNF acts as a 
neuroprotectant. It has been shown to rescue motor neurons from natural cell death, as well as 
prevent their death following axotomy (81, 82, 83). Indeed, external application of BDNF 
following axotomy or ventral root avulsion reduces motoneuron death (82, 84) and continuous 
dose-dependent administration of BDNF shows long-term survival effects on adult 
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motoneurons after sciatic nerve avulsion (85). Additionally, a few studies found that 
application of NGF, BDNF, and NT-3 can reverse detrimental changes induced by axotomy in 
adult and neonatal sensory neurons (86,86,88).   
The ability of BDNF to rescue motor neurons is carried out through its trkB receptor. 
Once BDNF binds to TrkB, three different signal transduction cascades are activated. These 
include insulin receptor substrate-1, Ras, protein kinase C, and many other intermediate 
proteins. BDNF signaling pathways activate one or more transcription factors (cAMP-
response-element-binding protein (CREB), and CREB-binding protein) which regulate the 
expression of genes encoding proteins that are involved in neural plasticity, stress resistance, 
and cell survival (89, 90, 91).  
4.2 Remyelination 
After Wallerian degeneration occurs, the next important step in peripheral nerve recovery 
is remyelination. Several studies have added exogenous BDNF to a peripheral nerve injury 
model and examined the effects on myelin protein synthesis and myelin sheath thickness. The 
first study to examine this phenomenon saw that when applied in combination with CNTF, 
exogenous BDNF increases myelin thickness of regenerating sciatic nerves (92). This work 
was continued by a study (93) that used a Schwann cell and dorsal root ganglion (DRG) cell 
co-culture model, as well as a sciatic nerve in vivo model, to test the effects of exogenous 
BDNF addition following an injury. Immediately following injury, BDNF caused an 
enhancement in the expression of myelin protein MAG and P0. This effect was seen in both 
the co-culture and sciatic nerve in vivo model. Consequently, when endogenous BDNF levels 
were reduced in the co-culture via addition of the receptor scavenger TrkB, myelin protein 
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synthesis was inhibited as was the formation of myelin, demonstrating that BDNF is indeed 
beneficial during remyelination.  
With the use of electron microscopy, Chan et al. demonstrated that the addition of BDNF 
increased the number of myelinating axons and the thickness of the myelin sheath in vivo (93). 
A similar study (94) created a mouse sciatic nerve injury model and administered exogenous 
BDNF injections to examine the effects on myelin sheaths in the distal nerve stump. Their 
results showed that mice receiving BDNF administration had an increased number of 
myelinated fibers and that myelin sheaths were thicker when compared to control mice. 
Additionally, mice receiving BDNF antibodies showed significant myelin deterioration in the 
distal sheath. Furthermore, a study by Zhang et al., 2000, demonstrated that treatment with 
BDNF antibody reduced the number and density of myelinated axons by 83%, and found that 
sensory reinnervation was impaired (95). Combined, these results demonstrate that BDNF is 
critical for preparing nerves for remyelination by increasing myelin proteins such as P0 and 
MAG, as well as protecting the distal nerve portion from atrophy by promoting remyelination.  
4.3 Axonal Sprouting, Regeneration, and Functional Recovery  
In addition to examining neuronal survival, regeneration, and re-myelination, several 
studies have looked at BDNF’s role during axonal sprouting. It has been shown that following 
severe trauma such as ventral root avulsion, exogenous BDNF significantly increases axonal 
sprouting (71). To support Gordon’s findings, another study found that application of BDNF 
antibodies to a transected facial nerve trunk significantly reduced axon sprouting up to 18% 
(96).  Axonal sprouting may increase in part, due to BDNF’s role as a guidance molecule for 
the growth cone at the end of each axonal sprout.  Studies in Xenopus spinal neuron models 
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show that BDNF and NT-3 can attract or repulse growth cones based on concentration 
gradients (97, 98). 
Although BDNF may increase axonal sprouting, the data is controversial in regards to 
increased functional return upon application of BDNF. For example, using the sciatic function 
index (99), gait analysis (100), and force recovery, several studies failed to demonstrate a 
return to function with exogenous BDNF. One study even showed that local long-term 
continuous infusion of low dose BDNF had no effect on tibial motoneurons after immediate 
microsurgical repair (101).  
On the other hand, a more recent study found that exogenous BDNF administration 
accelerates the recovery process in a mouse sciatic nerve injury model while BDNF antibody 
treatment delayed it (94). After the crush injury, control mice took 12 days to show initial 
improvement using the toe spreading score of gait analysis, and 24 days for a full recovery. 
Mice receiving the BDNF treatment required only 7 and 18 days, respectively. Conversely, 
BDNF antibody treatment delayed the processes to 17 and 30 days.   
Another study created control and heterozygote BDNF knockout mice that received a 
left sciatic nerve crush (102). Nerve function was evaluated using a rotarod test, sciatic function 
index, and motor nerve conduction velocity simultaneously with histological nerve analysis. 
Impaired nerve repair was observed in the BDNF heterozygote mice, which was consistent 
with attenuated function of BDNF. In contrast, the BDNF homozygote mice showed complete 
functional and histological recovery. These observations support the view that BDNF may play 
a pivotal role in functional return following a peripheral nerve injury.  
Unlike other neurotrophic factors, BDNF is unique in that it regulates and maintains 
neuronal function, and when given exogenously, it counteracts degenerative changes in both 
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sensory and motor axons. Unlike NGF, BDNF supports motoneuron survival in vitro, rescues 
from naturally-induced apoptosis, and prevents in vivo axotomy-induced cell death (103). 
While there are benefits of exogenous BDNF application to peripheral nerve lesion sites, its 
abilities to increase functional return are still controversial, which is why recent research has 
focused on the adjunct use of BDNF in combination with other therapies such as stem cell 
therapy, biomaterial conduits, pharmacotherapy, etc. A more in-depth discussion of BDNF 
therapy combined with stem cell use will be included in sections 6 and 8.  
5.  Cell Based Therapy for Improving Nerve Regeneration 
As discussed above, the gold standard of peripheral nerve repair continues to be the use of 
nerve grafting combined with direct nerve repair, and occasionally, the use of conduits to 
bridge larger nerve gaps. Recent research, however, has focused on cell therapy as a promising 
therapeutic approach for promoting nerve regeneration. Particularly, cell-based therapy has 
been widely studied as a source of growth-promoting molecule delivery system and graft 
replacement. This section will focus briefly on the past use of glial cells such as Schwann cells 
and then discuss the promising potential of bone marrow mesenchymal stem cells.  
5.1 Use of Schwann Cells 
Schwann cells (SCs) play a key role in axonal regeneration, making them an attractive cell 
type to use for transplantation. During Wallerian degeneration, Schwann cells remove necrotic 
tissue and myelin debris together with macrophages (104). In the regeneration phase, glial cells 
form the Bünger bands which physically guide axons to distal innervation targets. 
Additionally, SCs increase synthesis of surface cell adhesion molecules and basement 
membrane proteins such as laminin and fibronectin (105). Schwann cells also produce 
neurotrophic factors, cytokines, and other compounds which promote neurite growth (106, 
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107).  Experimental evidence shows that transplantation of SCs in vitro supports axonal 
outgrowth (4), and improves the quality and rate of axon regeneration (5,6,7).  Schwann cells 
combined with a vein conduit have even been used in bridging long nerve gaps (108, 8).  
Although Schwann Cells would be an ideal source of cell therapy, there are several 
technical limitations hampering their use in clinical trials. In the case of acute nerve injuries, 
use of Schwann cells would be impractical as the time requirement for expanding autologous 
cells in culture is lengthy (9). Additionally, there is a risk of fibroblast contamination which 
would lead to unwanted scarring of the nerve (7).  In order to obtain a source of autologous 
SCs, another healthy nerve must be sacrificed for harvesting, making donor site morbidity 
another concern. All of these limitations have led researchers to seek for a better alternative to 
SCs for cell transplantation and stem cells have been posed as better candidates.  
5.2 Mesenchymal Stem Cells 
Stem cells are a distinct population of undifferentiated cells which are characterized by 
potency, the ability to differentiate into a wide variety of specialized cell types, and the ability 
to undergo numerous rounds of mitosis while remaining undifferentiated. There are embryonic, 
fetal, and adult stem cells, of which this review will focus on adult stem cells.  
Of all three types, adult stem cells are thought to be the most limited in their potency since 
their primary role is to repair damaged tissue in which they are found (11). Unlike fetal and 
embryonic stem cells, adult stem cells raise fewer ethical concerns as they do not require 
human embryo destruction. Additionally, adult stem cells have a lower risk of tissue rejection 
as auto-transplantation is a possibility, and the small risk of teratoma formation that embryonic 
stem cells presents is almost null with adult cells (109).  Common sources of adult stem cells 
include mesenchymal, hematopoietic, or umbilical cord derived. In particular, bone marrow-
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derived stem cells are known as mesenchymal stem cells and can differentiate into connective 
tissue types such as chondrocytes, adipocytes, myocytes, osteocytes, fibroblasts, and tenocytes 
(110). There is also extensive additional research to suggest that MSCs have the ability to 
transdifferentiate into ectodermal and endodermal lineages such as glial cells, neurons, 
hepatocytes, etc (Fig. 2) (111, 112, 113).  In addition to being a source for many cell types,  
 
Figure 2. The potential of Mesenchymal stem cells to transdifferentiate into other cell 
lineages. Adapted from (11).  
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MSCs are easily accessible and have the ability to rapidly divide under culture, allowing them 
to meet the requirements of an in vitro cell system. Additionally, MSCs are excellent 
candidates for allogenic transplantation as they are immune privileged cells and do not require 
the use of immune suppressive drugs (11). Other advantages include the capacity of MSCs to 
release paracrine factors, survive and integrate into host tissue, concentrate in injured tissues, 
and their high safety and efficacy (114).  
6.   Mechanisms behind Nerve Regeneration potential of MSCs 
Although MSCs are highly regarded for their plasticity and ability to differentiate into 
many cell types, there are other mechanisms by which MSCs are thought to promote and  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Various proposed mechanisms of neuronal support by MSCs. Adapted from (11).  
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support nerve regeneration. Such mechanisms include immunomodulation, transdifferentiation 
into SCs, paracrine secretions, genetic manipulations, or mitochondrial transfer/cellular fusion 
(Fig. 3).  
6.1 Secretion of Neurotrophins 
As discussed already, neurotrophins promote neuronal survival, help to reverse the 
negative effects of PNIs, and lead to Schwann cell proliferation and differentiation. One of the 
key ways that MSCs are thought to help in regeneration is through paracrine production of 
neurotrophic substances.  A recent proteomic study (115) studied DRG explants and neurons 
co-cultured with MSCs and showed enhanced neurite outgrowth and neuronal cell survival due 
to the production of NGF, CNTF, BDNF, and basic fibroblast growth factor (bFGF) by MSCs. 
In the culture system, there was no direct contact between the neurons/explants and MSCs, 
leading researchers to believe that positive effects were due to the release of soluble growth 
factors.  A similar study found that dorsal root ganglion explants treated with MSC-conditioned 
media also showed increased neurite outgrowth, presumably due to the presence of growth 
factors in the media (15).  In addition to their direct paracrine effects, MSCs can induce SCs 
to produce neurotrophic mediators as well. In co-culture studies of rat SCs and MSCs, 
increased survival and proliferation rates of SCs was noted as well as high expression mRNA 
and protein levels of NGF, BDNF, and Trk/p75NTR receptors (16). The same group also 
examined the effect of MSCs on Schwan cells in a rat peripheral nerve repair model and 
showed that MSCs increased the generation of SCs and promoted SC-mediated neurotrophic 
functions.  
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After in vitro co-culture studies, the next step was to determine whether or not 
implanted MSCs continued to produce growth factors in vivo and if these factors were 
biologically active. Several studies were able to document expression of GDNF, CNTF, FGF, 
and even BDNF by MSCs in vivo, allowing for survival and elongation of the growth cone 
(116, 117, 17, 118). A similar study (15) implanted MSCs at a rat sciatic nerve lesion and the 
results demonstrated improved regeneration of motor and sensory axons due to the production 
of growth factors. Other studies incorporated conduits filled with mesenchymal stem cells in 
order to test models of long sciatic nerve gaps. For example, one group implanted a collagen 
conduit filled with MSCs at a mouse sciatic nerve transection lesion and saw enhanced axon 
regeneration and remyelination (17). Additionally, high levels of NGF and BDNF were 
detected, suggesting that MSCs were expressing these neurotrophins in vivo.  
Combined, these results demonstrate that MSC-based therapy improves peripheral 
nerve regeneration through direct secretion of neurotrophic factors which may act locally as 
well as on glial cells further away.  
6.2 Immuno-modulatory effects 
One of MSCs most interesting features is their ability to modulate the immune system. 
When transplanted into tissues, MSCs actually decrease tissue inflammation and can have 
immunosuppressive effects by suppressing T-cell proliferation and inhibiting natural killer T 
cell signaling (119). Additionally, MSCs promote anti-inflammatory T helper 2 cells (120). 
MSCs also suppress monocyte differentiation into dendritic cells, thus decreasing the amount 
of antigen presentation to T cells (121). In a spinal cord injury model, MSC transplantation 
favored the development of M2 macrophages and suppressed M1 activation (122). M2 
macrophages have anti-inflammatory activity while the classic M1 phenotype has deleterious 
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effects in damaged tissue (122). The complex mechanisms behind MSCs immunomodulatory 
properties are still being uncovered but their ability to decrease inflammation has been widely 
described, supporting the therapeutic merits of stem cells.  
6.3 Cellular Fusion 
In addition to the various nerve regeneration mechanisms discussed, a few studies have 
documented the spontaneous transfer of mitochondria from MSCs with a variety of other cell 
types. MSCs can form tunneling nanotubes through which mitochondria and nuclear DNA can 
be transferred. Several studies have utilized MSCs in acute pulmonary damage models to 
demonstrate mitochondrial transfer from MSCs to alveolar cells and airway epithelial cells 
(123, 124, 125). Mitochondrial transfer has also been demonstrated between mesenchymal 
stem cells and cardiomyocytes, causing increased proliferation and, in Acquistapace’s study, 
reprogramming towards a progenitor-like state (126, 127,128). The majority of these studies 
involve use of epithelial or muscle cells; however, one study found that bone marrow derived 
MSCs were able to fuse with neuronal cell types, including Purkinje cells (129).  To date, there 
is no evidence of mitochondrial transfer or MSC fusion with Schwann cells, but this could 
represent an alternative mechanism by which MSCs support Schwann cell activity and 
regeneration.  
7. Clinical Trials with MSCs for Neurological Disorders 
Extensive in vitro and in vivo data suggest that mesenchymal stem cells secrete several 
trophic factors, support neuritogenesis and neurite growth, and promote survival and 
elongation of damaged peripheral nerves. An even larger body of work exists, demonstrating 
the benefits of MSCs within the context of central nervous system disorders and spinal cord 
trauma, which is not covered in this review. Combined, the data has proven the safety and 
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efficacy of MSCs and allowed the cells to be used in human clinical trials, which is a key 
stepping stone to them being commonly used as a clinical therapy.  
A large number of studies have reported the use of MSCs in treatment of neurological 
disease and trauma (130).  Clinical trials range from treatment of Multiple Sclerosis to 
Alzheimer’s disease to treatment of traumatic injury, with spinal cord injury models having 
the largest number of trials (Fig 4.) (131).  
For clinical treatment of spinal cord injuries, Ra et al. conducted a phase 1 clinical trial 
in which eight patients who had suffered a spinal cord injury were infused with autologous 
adipose MSCs (133). After three months, no unwanted side effects were noted. A more recent 
phase 1 trial involved 14 patients with chronic spinal cord damage who received autologous 
injections of bone marrow MSCs.  Patients displayed improvements in tactile sensitivity and 
over 50% of patients had increased lower limb motor function (134). Altogether, these clinical 
trials show promising uses for autologous MSCs in treating spinal cord injuries, as well as for 
central nervous system disorders including ALS and MS.  
Fewer clinical trials have utilized mesenchymal stem cells within a peripheral nerve 
context. The few trials that have been performed focus on diabetic peripheral neuropathy 
patients.  For diabetic patients, MSCs are an effective therapeutic agent due to secretion of 
bFGF and VEGF, and their potential to differentiate into neural cells such as astrocytes, 
oligodendrocytes, and Schwann cells (135). Current clinical trials are in stage II and III and 
revolve around change of nerve conduction velocities before and after stem cell IV transfusion. 
The results have yet to be published. There are no current clinical trials examining the use of 
MSCs in traumatic peripheral nerve damage, which may be another large area for future 
clinical use.  
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Figure 4.  The percentage of MSC-based clinical trials classified by disease type followed by 
a subclassification of MSC-based clinical trials for neurological disease only. Adapted from 
(131).  
The data obtained from clinical trials, as well as in vitro and in vivo studies shows that 
unaltered MSCs offer many benefits for nerve regeneration, mainly by secretion of 
neurotrophic factors, as well as by support of Schwann cells. However, MSCs may hold even 
greater potential when transdifferentiated into another cell type, such as Schwan cells. The 
various benefits and methods of transdifferentiated MSCs will be discussed below.  
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8.Transdifferentiation  
Bone mesenchymal stem cells were once thought to be fairly restricted in their 
differentiation patterns but more studies are demonstrating that they are endowed with 
versatility and greater plasticity. In response to a variety of culture conditions, specialized in 
vivo microenvironments and genetic manipulations, MSCs can turn into different phenotypes 
such as glial cells. In particular, turning MSCs into a Schwann cell-like phenotype is of high 
interest due to the beneficial effects on nerve regeneration.  MSCs can be transdifferentiated 
with a variety of methods, including the use of transplantation, small molecule cues, genetic 
manipulation, or as most recently described, through electric stimulation. Each method will be 
discussed in greater detail below.  
8.1 Transdifferentiation via transplantation 
During Wallerian degeneration and nerve regeneration, a wide variety of cytokines and 
growth factors are released, creating a specialized microenvironment which has the capacity 
to greatly influence cell differentiation patterns. Although controversial, these environmental 
signals have been utilized to transdifferentiate MSCs in response to injury or inflammation.  
Bone marrow derived MSCs injected at the site of a rat sciatic nerve transection were capable 
of surviving and migrating, as well as differentiating into an SC-like phenotype, based off of 
S100 immunoreactivity patterns (10). In this study, it was presumed that MSC 
transdifferentiation occurred in response to physiological environmental cues, as no MSC 
medium changes were made. Although transdifferentiation may have occurred, the percentage 
of cells positive for S100 was so low that this may not be a very efficacious method. Another 
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2010 study demonstrated similar results, with few numbers of transplanted MSCs at an injury 
site converting to an SC-like phenotype (136).  
8.2 Transdifferentiation via co-culture 
A more simplistic approach to changing a cell’s microenvironment is to adjust its 
neighboring interactions using co-culture methods. One study showed that direct contact co-
cultures of DRG neurons and MSCs could cause a phenotypic and morphological change in 
MSCs to resemble Schwan cells (137). Researchers suggested that the release of cytokines and 
other neuronal molecules on the axonal surface may play a role in the transdifferentiation 
process. However, this method alone did not allow tMSCs to form compact myelin, suggesting 
that further molecular cues are necessary for a complete transdifferentiation process. Another 
study looked at co-culture of MSCs with olfactory ensheathing cells and saw a dramatic 
increase in the number of MSCs resembling a neural morphology which were immunoreactive 
to various neural markers such as GFAP, p75NTR, and MAP2 (12). These studies demonstrate 
that a co-culture method may be sufficient to begin the transdifferentiation protocol, but 
additional small molecules may be needed to affect a functional change in tMSCs.  
8.3 Use of small molecules in media 
Although transdifferentiation via transplantation and co-culture has shown some 
success, this method is not as successful or efficient as the addition of small molecules to 
culture medium. These specific molecules can trigger cell-signaling pathways and rapidly 
modulate cell phenotype. In 2001, Dezawa et al., discovered a cell medium protocol for 
transdifferentiation of MSCs into an SC-like morphology(138). After induction, these cells 
physically resembled SCs and expressed several Schwann cell markers. 
Newer studies have utilized compounds such as valproic acid and other histone deacetylase 
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inhibitors along with neural inducing signaling molecules to create mature neural cells (139). 
A 2014 study used a two-step method to first create neural precursor cells, and then induced 
Schwann cells from human foreskin fibroblasts (13). These cells may potentially be used to 
treat peripheral nerve injuries in the future.  
8.4 Genetic modification for transdifferentiation 
A newer transdifferentiation method can now convert adult differentiated cells to a specific 
terminal cell type without going through pluripotency. This newer methodology is based on 
the idea of ‘master control genes’ in somatic cells which can be overexpressed to induce a 
cascade of cell fate changes (140, 141, 142). The earliest evidence of this possibility was 
provided by Weintraub et al, who confirmed conversion of fibroblasts to myogenic lineage by 
transfection of a master regulatory gene (MyoD) (143). Later, Pax6 was recognized as a master 
gene responsible for neuronal differentiation. Vierbuchen et al. identified the combination of 
Asc11, Brn2 and Myt11 as able to convert mouse embryonic fibroblasts into mature neurons 
(144). Unfortunately, this method of generating target cells through transdifferentiation relies 
on viral expression of exogenous transcription factors which makes demonstration of safety 
for clinical trials difficult; however, the method holds promise for direct cellular conversion. 
8.5 Electrical Transdifferentiation 
Finally, a very recent study by Das et al., 2017 described a novel procedure for 
transdifferentiation of MSCs through the application of electrical stimuli via graphene-based 
electrode (145). Rat MSCs were immobilized on a graphene interdigital electrode and 
subjected to either electrical or chemical transdifferentiation, then expression of cell surface 
markers such as p75, S100, and S100β was analyzed with immunocytochemistry after 15 days. 
The results for electrical tMSCs were compelling, showing the highest degree of preferential 
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immunolabeling, with more than 85% of cells demonstrating staining for SC markers vs. 75% 
for chemically transdifferentiated MSCs. Additionally, electrically stimulated cells secreted 
significantly higher levels of NGF as compared to their chemically transdifferentiated counter-
parts. Although not statistically significant, higher levels of BDNF and GDNF were also noted. 
While other reports have shown that electrical stimulus can increase growth factor level 
production in Schwann cells (146, 147, 148), this paper is the first to describe such effects in 
transdifferentiated MSCs. Furthermore, Das et al., demonstrated that electrical stimuli alone 
can transdifferentiate MSCs to an SC-like phenotype without the need for chemical growth 
factors, thus saving researchers time, labor, and money, while providing a novel system for an 
artificial neural network circuit.  
8.6 Beneficial properties of tMSCs 
 Once methods of transdifferentiation had been discovered, scientists moved on to in 
vivo studies to determine the effect of tMSCs on models of peripheral nerve injury. Once 
Dezawa et al. performed their in vitro cell characterization, tMSCs were transplanted into the 
cut end of a rat sciatic nerve. Results showed that the transplanted cells remained in a Schwann-
cell like state and were capable of forming myelin sheaths, as well as supporting nerve fiber 
regrowth (111). Additionally, Dezawa and collaborators also showed that tMSCs colocalized 
with the myelin-associated glycoprotein antibody signal, suggesting that MSCs may be able to 
differentiate into myelinating cells.  After this initial trial, many labs followed suite by 
implanting transdifferentiated MSCs into a variety of peripheral nerve and spinal cord injury 
models. In 2004, Mimura et al. supported Dezawa’s work by showing that human and rodent 
MSC-derived Schwann cells expressed myelin-related markers and contributed to re-
myelination when transplanted into a rat sciatic nerve injury (149). Using a similar 
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transdifferentiation protocol, Keilhoff et al. (2006) also demonstrated that transplanted tMSCs 
within a muscle conduit promoted remyelination, and electron microscopy showed that single 
tMSCs were even capable of wrapping more than one axon, similar to an oligodendrocyte (18).  
In addition to providing functional support, transdifferentiated MSCs are capable of 
producing trophic factors at even higher levels than Schwann cells. When transdifferentiated 
MSCs were placed in a DRG co-culture system without direct contact, tMSCs showed 
upregulation of BDNF and NGF. Additionally, neurite outgrowth was observed even in the 
presence of NGF and BDNF blocking antibodies, suggesting that other trophic cytokines or 
factors may be produced by tMSCs (150). Another interesting study used a combination of two 
different mediums to transdifferentiate MSCs, causing them to produce large amounts of 
BDNF and GDNF. Interestingly, cells resembled an astrocyte morphology and expressed 
certain astrocyte markers. When transplanted, the cells improved muscle reinnervation and 
restored motor function in a rat sciatic nerve crush model (14). Combined, these results confirm 
that MSCs display functional characteristics similar to SCs by secreting bioactive 
neurotrophins. 
Soon after the introduction of tMSC transplants, scientists began to question the 
duration of a Schwann cell-like state once cells were placed in an in vivo environment. A study 
by Shimizu et al., 2007 transplanted MSC Schwan-like cells within a transpermeable tube into 
a rat sciatice nerve gap (151). After three weeks, tMSCs continued to express SC markers such 
as p75, GFAP and increased S100 expression. Most importantly, the MSCs expressed myelin-
associated markers such as MAG and MBP even after three weeks in vivo, which the authors 
contend supports the thesis that MSCs may retain SC-like characteristics even after 
transplantation. It is important to note however, that remeylination was not seen via IHC or 
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electron microscopy, as in other studies. A different study by Ishikawa et al., 2009 transplanted 
MSC-derived Schwann cells within chitosan gel sponges and found that cells were able to form 
myelin sheaths one month after transplant (152). The mean diameter of myelinated fibers 
increased continuously, even out to four months post-transplant. This study, along with the 
work by Dezawa et al., 2001, demonstrates that rat tMSCs may contribute to remyelination 
after transplantation into an injured PNS model. Similar results have been found in spinal cord 
injury models (153, 154, 155), indicating that MSC-derived Schwann cells are effective for 
both PNS and CNS regeneration. These studies suggest that MSCs are capable of expressing 
Schwann cell biomarkers, may express myelin markers, and may even physically form myelin 
sheaths. Moreover, these effects may last well past the time that MSCs were last exposed to 
transdifferentiation media, suggesting that the acquired Schwann cell-like state is at least semi-
permanent and allows cells to persist well into the acute phase of Wallerian degeneration.  
Unfortunately, there have never been clinical trials involving the use of chemically 
transdifferentiated MSCs for the nervous system. However, a primate study has been 
completed as an important pre-clinical step. Wakao et al. 2009 used a monkey model and 
followed subjects out to a year post transplant (156). MSCs were chemically induced to 
resemble Schwan cells and cell marker expression patterns were confirmed with both 
immunocytochemistry and reverse transcription-PCR. Cells were transplanted for one year in 
a median nerve transection model. During this year, no major health abnormalities were 
observed in the monkeys. Ki-67 immunostaining revealed no signs of massive proliferation 
and the 18F-FDG-PET scan which detects neoplastic cells, demonstrated no abnormalities. 
Furthermore, monkeys regained function, and electrophysiology with histology revealed 
restoration of the severed nerve. This study is particularly important because it demonstrated 
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not only the efficacy of transdifferentiation, but also the safety of long term implantation of 
tMSCs.   
9. Genetically modified MSCs 
The literature has aptly demonstrated that undifferentiated MSCs can produce 
neurotrophins in vitro as well as in vivo and that the process of transdifferentiation can even 
further increase production levels. Only in recent years have researchers begun to investigate 
the continuous production of these proteins via functional gene insertion. As one of their novel 
features, MSCs are suitable for transduction and expression of exogenous genes, making them 
a good candidate system for genetic engineering. The most widely used systems are now either 
lentivirus or retrovirus based. In regards to nervous system disorders, MSC lines have been 
created to over express a wide variety of neurotrophins such as GDNF, NGF, and BDNF (19), 
as well as other growth factors.  Pre-clinical studies by Sharma et al., 2015, demonstrated that 
genetically modified MSCs (BDNF-GFP) had similar viability and proliferation rates when 
compared to non-genetically modified MSCs (157).  One 2009 study by Bauer et al., even went 
so far as to develop an in depth biosafety model to specifically assess the risk of retro- and 
lentiviral vectors (158). Human hematopoietic stem cells and MSCs were transduced with 
Moloney murine leukemia virus and transplanted into 481 immunodeficient mice. There was 
no detectable evidence of insertional mutagenesis leading to human leukemias or solid tumors 
during the 18 months animals were studied. Additionally, no vector-associated adverse events 
were observed and in 117 serum samples analyzed, there was no detectable viral DNA.  These 
findings indicate that virally transfected MSCs are stable and may act biologically similar to 
the wild type MSC population, making them suitable for in vivo study use in a variety of disease 
and injury models. Genetically modified MSCs have been used in studies ranging from the 
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treatment of neurodegenerative disorders, to ischemic injury, to spinal cord crush injuries and 
peripheral nerve transections. Studies in each of these areas will be discussed below.  
9.1 Use of genetically modified MSCs in neurodegenerative disorders 
Parkinson’s Disease 
Use of glial derived neurotrophif factor (GDNF) was first described in 1993 as a 
potential treatment for Parkinson’s disease because of its ability to increase dopamine uptake 
and aid in the survival of embryonic midbrain dopaminergic neurons (159). With the challenge 
of administering GDNF infusions, cell based strategies to deliver GDNF have received recent 
attention. In a recent study, MSCs transduced with a GDNF retrovirus vector increased 
dopaminergic neuron sprouting (160). A similar study found that injections of GDNF MSCs 
given one week before a lactacystin lesion of the medial forebrain also significantly increased 
dopamine levels (161). Furthermore, Ren and colleagues (2013) transplanted GDNF MSCs 
into the brain of non-human primates and saw increased dopamine levels and improved 
contralateral limb function (162). Preclinical studies provide evidence that GDNF MSCs 
provide high levels of a functional trophic factor, which, with further safety and efficacy data, 
could be used in clinical trials as adjunct treatment for Parkinson’s disease.  
Alzheimer’s Disease 
Treatment options for Alzheimer’s disease are limited and focus on symptoms related 
to neurotransmitter systems, rather than targeting the underlying pathologies. Given the 
prevalence of the disease and lack of treatments, new strategies are being developed which 
focus around the use of nerve growth factor. Autologous fibroblasts engineered to express NGF 
were transplanted in eight patients with Alzheimer’s. Patients saw an improvement of Mini-
Mental Status Examination scores and a reduced decline in cognitive scores (163). A phase II 
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clinical trial is still open for this method (19). MSCs have not directly been used in human 
clinical trials yet, however, promising work by Li et al. (2008) demonstrated reduced memory 
deficits in the Morris-water-maze task in a rat model when NGF MSCs were transplanted to 
the hippocampus (164).  The next step in research should include further in vivo transplantation 
trials with NGF MSCs in both rat and human models.  
Huntingtin’s Disease 
Compared to the other neurodegenerative diseases discussed, Huntington’s disease is 
unique in that clinical signs may be directly correlated to reduced levels of a neurotrophic 
factors, BDNF.  Low BDNF levels in the striatum are due to loss of function of the wild-type 
huntingtin protein. This protein modulates BDNF transcription and plays a role in BDNF 
transport and secretion (165). The Dunbar laboratory first demonstrated that murine MSCs 
engineered to overexpress BDNF improved disease progression on a transgenic mouse model 
of Huntingtin’s (166).  Important pre-clinical trials by Pollock et al., 2016 utilized a double-
blind study to examine the effects of transplanted human BDNF MSCs on disease progression 
in a mouse Huntingtin’s disease model (167).  Treatment with MSCs decreased striatal atrophy 
and significantly reduced anxiety. BDNF MSC treatment also increased the mean lifespan of 
mice. This study demonstrated the efficacy of BDNF hypersecreting MSCs as a medical 
therapy for Huntingtin’s disease and set the groundwork for future clinical trials.  
9.2 MSCs for Ischemic Brain Injury 
Ischemic brain injury causes the death of various important cell types such as neurons, 
glial, and endothelial cells. Regain of function and brain tissue repair necessitates cell 
replacement and formation of a new network (168). When transplanted into ischemic regions 
of the rat brain, MSCs reduced functional deficits after 14 days, scar thickness was decreased, 
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and the number of proliferating cells in the subventricular zone was increased (169, 170, 171).  
Improvement by MSC treatment has been attributed to decreased apoptosis, MSC 
differentiation into neuronal cells, and promotion of neurogenesis, angiogenesis, and 
synaptogenesis (172, 173, 174, 175). Several groups have used genetically modified stem cells 
that overexpress growth factors known to enhance neuronal survival. One of the first factors 
studied in MSCs was BDNF and GDNF. When BDNF overexpressing MSCs were delivered 
to an ischemic brain model via injection, infarct volume was reduced and functional outcome 
was improved (176, 177, 178). Furthermore, BDNF expressing MSCs can significantly 
improve behavioral test results and reduce ischemic damage via MRI analysis after 7 and 14 
days (177, 179). 
9.3 Spinal Cord Injuries 
In addition to various therapies within the brain, modified MSCs have been used with 
variable success in the spinal cord.  In a 2005 study by Lu, Jones, and Tuszynski, BDNF MSCs 
were injected into a crushed spinal cord injury and the extent and diversity of axonal growth 
was increased (180). Additionally, Schwann cells preferentially migrated to the BDNF 
secreting grafts.  Unfortunately, functional recovery was not achieved for any of the studied 
rats. A similar study was performed by Sasaki et al., 2009, in which BDNF secreting human 
MSCs were implanted at a T9 spinal cord lesion (181). After five weeks, locomotor 
improvement was observed for the BDNF group and there was increased axonal sprouting. 
Specifically, an increased number of serotonergic fibers were observed in the ventral horn grey 
matter, an area important for motor controlled movement. Unlike the 2005 Lu study, Sasaki’s 
group demonstrated that BDNF MSCs are associated with improved functional outcome 
following a spinal cord injury. Due to the conflicting data reports, additional studies are 
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necessary before the full benefits of BDNF can be determined for the treatment of spinal cord 
damage.  
9.4 Peripheral nerve injury 
Of all the disease models discussed so far, peripheral nerve injuries have the fewest 
published studies involving transplantation of genetically modified MSCs.  This may be due 
to the fact that researchers are now utilizing a multi-disciplinary approach and studies often 
involve the use of engineered conduits, cell transplants, and now even gene therapy. One of 
the first studies to use a MSC gene delivery system transplanted MSC spheroids transfected 
with the BDNF gene (182). Spheroids were combined with a polymeric nerve conduit to bridge 
a 10 mm rat sciatic nerve transection gap. MRI was used to track the transplanted cells. 
Animals receiving the BDNF MSC spheroids had the shortest gap bridging time, the largest 
regenerated nerve, and the thickest myelin sheath at 31 days. Furthermore, BDNF spheroids 
significantly promoted functional recovery. Another, more recent study (183), combined 
multi-channel agarose scaffolds with BDNF MSCs to bridge a 15 mm sciatic nerve transection 
gap. Additionally, the distal sciatic nerve segment was injected with the BDNF lentiviral 
vector. Twelve weeks after injury, BDNF secreting cells significantly increased axonal 
regeneration and injection of the lentiviral vector at the distal segment enhanced axonal 
regeneration beyond the lesion. Finally, a newly published February 2017 study actually 
looked at the efficacy of BDNF ex vivo gene transfer to umbilical cord blood derived MSCs in 
a rat sciatic nerve crush injury model (184). Four weeks post-surgery, the BDNF expressing 
MSCs exhibited more peripheral nerve regeneration than the controls. Additionally, sciatic 
function index, axon counts, and axon density were significantly increased for both the BDNF 
MSC and regular MSC groups. The results from these works are promising and indicate that 
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in particular, BDNF hypersecreting MSCs can improve sciatic nerve regeneration. Unlike other 
areas of research, no pre-clinical characterization studies looking at safety and appropriate 
dosage ranges have been published and this would be a necessary next step before BDNF 
MSCs could be tested outside of a rat model.  
10. Conclusions and Future Directions 
Peripheral nerve injury limits mobility and sensation in up to 2.8% of all trauma patients 
and often results in unsatisfactory return to function (185). Although the gold standard of 
microsurgery with autograft has seen advances in the last decade, there are significant 
drawbacks associated with the procedure. For this reason, scientists have proposed the use of 
an alternative transplant type, in the form of autologous stem cells. Specifically, research is 
directed at the conversion of mesenchymal stem cells towards a Schwann cell-like fate in order 
to aid in Wallerian degeneration, neuronal regeneration, and possibly even remyelination. 
Additionally, MSCs have their own unique benefits such as immunomodulatory properties, 
secretion of neurotrophic factors, possible mitochondrial transfer, and the ability to be easily 
genetically modified. In order to resemble a Schwann cell, MSCs must undergo 
transdifferentiation which can be achieved through a variety of methods including 
incorporating specific factors into the growth media, co-culture method, in vivo 
transdifferentiation, and others. Although these older techniques have their benefits, methods 
of transdifferentiation have changed drastically within the last ten years and now include 
master gene modification and the use of specific cell signaling molecules combined with 
histone deacetylase inhibitors.  
As demonstrated by the newer body of literature, scientists are beginning to move away 
from the use of bone marrow MSCs and are instead using a cell type which is even easier to 
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harvest such as fibroblasts, adipocytes, and even hair follicle stem cells (186, 187,13).These 
studies rely largely on immunocytochemical staining, co-culture neurite outgrowth, and gene 
expression patterns to support transdifferentiation of cells into Schwann cells. Unfortunately, 
none of these studies have measured growth factor secretion levels from transdifferentiated 
cells, and only Thoma’s study looked at the ability of these cells to create myelin. In order to 
truly assess whether or not these transdifferentiated cells are Schwann cells, future work should 
test growth factor secretion, perform patch-clamp recordings, transplant cells into rat sciatic 
nerve models, and examine myelin formation via electron microscopy (188).  
In addition to testing new cell types, researchers are trying new methods of 
transdifferentiation and emphasizing the use of genetic control and epigenetic cues. Future 
research may focus on Schwann cell de-differentiation or multi-step transdifferentiation in 
which a less-differentiated intermediate is first created, and then the fully transdifferentiated 
cell type is achieved, such as in Thoma et al.’s work with fibroblasts. While these cell fate 
reprogramming methods are promising, they can often be time consuming, difficult to 
consistently reproduce, and cost prohibitive. Additionally, studies have yet to be performed 
which examine the tumorigenic capacity of these cells and their long term genetic stability.  
While the field of transdifferentiation still has many challenges to overcome, it is a promising 
focus in the study of regenerative medicine and offers new insight into cell fate plasticity. 
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Specifically, in regards to the peripheral nervous system, researchers have shown that a variety 
of regenerative cell types may act like Schwann cells by secreting trophic factors, supporting 
re-myelination, and decreasing time to functional return of severed nerves. Additionally, when 
transdifferentiated cells are combined with multiple neuro-regenerative strategies such as ex 
vivo gene delivery, and biomaterial conduits, they may become powerful alternatives to 
traditional peripheral nerve regeneration therapies.  
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1.  Abstract 
The use of genetically modified mesenchymal stem cells (MSCs) is a rapidly growing 
area of research targeting delivery of therapeutic factors for neuro-repair. Cells can be 
programed to hypersecrete various growth/trophic factors such as brain-derived neurotrophic 
factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and nerve growth factor 
(NGF) to promote regenerative neurite outgrowth. In addition to genetic modifications, MSCs 
can be subjected to transdifferentiation protocols to generate neural cell types to physically and 
biologically support nerve regeneration.  In this study, we chose to combine these two different 
strategies and evaluated the impact of transdifferentiating genetically modified MSCs into a 
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Schwann cell-like phenotype.  After 8 days in transdifferentiation media, approximately 30-
50% of transdifferentiated BDNF-secreting cells immunolabeled for Schwann cell markers 
such as S100, S100β, and p75NTR. Similar results were observed 20 days after inducing 
transdifferentiation with minimal decreases in expression levels. BDNF production was 
quantified by ELISA, and its biological activity tested via the PC12-TrkB cell assay.  
Importantly, the bioactivity of secreted BDNF (45.2 ng/mL/106cells/day) was verified by the 
increased neurite outgrowth of PC12-TrkB cells. These findings demonstrate that not only is 
BDNF actively secreted by the transdifferentiated BDNF-MSCs, but also that it has the 
capacity to promote neurite sprouting and regeneration. Given the fact that BDNF production 
remained stable for over 20 days, we believe that these cells have the capacity to produce 
sustainable, effective, BDNF concentrations over prolonged time periods and should be tested 
within an in vivo system for future experiments. 
2. Introduction 
Peripheral nerve injuries occur as the result of sudden trauma and can lead to loss of 
sensory and motor function to peripheral limbs (1). Many surgical procedures are available to 
halt the propagation of nerve damage, and the adoption of a particular procedure depends on 
the extent of injury. Epineural sutures are considered the standard of care in the case of 
transection injuries (2). Another surgical procedure, autologous nerve grafting, is widely used 
in cases of gap formation (2, 3, 4). Although these surgical procedures provide many benefits, 
there are still considerable limitations associated with them such as donor site morbidity, 
neuroma formation, fascicle mismatch, and scarring (5). To overcome such restrictions, 
researchers have explored various avenues to improve post-surgical outcomes(6, 7, 8, 9, 10, 
11). The most commonly studied methods include: cell transplantation, delivery of growth 
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factors which stimulate regenerating axons, and implanting nerve regeneration conduits 
containing replacement cells at the site of injury (7, 12, 13, 14). Schwann cells (SCs), which 
are peripheral glial cells, play an important role in nerve regeneration by clearing out debris 
from the site of injury. Additionally, they release growth factors to stimulate myelination and 
axonal regeneration (15, 16). Various cell types including embryonic stem cells (17), umbilical 
cord-derived stem cells (18), bone marrow-derived mesenchymal stem cells (MSCs)(19), 
adipose-derived stem cells (20), olfactory ensheathing cells (21), and dental pulp-derived stem 
cells (22) have been transplanted to replace native SCs, and each has reported enhanced nerve 
regeneration. Mesenchymal stem cells in particular are preferred due to benefits like 
autologous transplantation, routine isolation procedures, and paracrine and 
immunomodulatory properties [17-19].   Mesenchymal stem cells have been transplanted at 
the site of injury either directly in their native form (undifferentiated) or in a SC-like form 
(transdifferentiated).  Additionally, some studies have transplanted ex-vivo genetically 
modified MSCs that hypersecrete growth factors normally secreted by Schwann cells during 
axonal regeneration (23). Here we chose to focus on brain-derived neurotrophic factor (BDNF) 
delivery because it has been shown to provide neuroprotection and facilitate the rescue and 
repair of damaged neurons (24, 25, 26, 27) . BDNF is responsible for neurogenesis and helps 
with survival and growth of various types of neurons such as dorsal root ganglion neurons and 
cortical neurons. It is also widely explored as a therapeutic agent to target various 
neurodegenerative conditions (28, 29).In this study, we chose to evaluate the impact of 
transdifferentiating BDNF hyper-secreting MSCs. Previously, we modified undifferentiated 
mesenchymal stem cells to hypersecrete neurotrophic factors such as brain-derived 
neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF)(30). 
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Additionally, we successfully transdifferentiated these MSCs into an SC-like phenotype on 
micropatterned substrates (31). Furthermore, MSCs transdifferentiated to SC-like cells have 
been shown to enhance peripheral nerve regeneration in a number of studies (32, 33, 34, 35). 
Here, we synergistically combined genetic modification and transdifferentiation to create 
MSCs that facilitate neurite outgrowth. These transdifferentiated MSCs showed various SC-
like characteristics such as bipolar spindle-shaped morphology, expression of SC marker 
proteins (S100, S100, and p75NTR) and increased release of BDNF. In this study, we 
successfully transdifferentiated BDNF-hypersecreting MSCs into a SC-like phenotype and 
quantified their morphological, molecular, and functional changes.  
3. Materials and Methods 
Mesenchymal Stem Cell Isolation and Culture 
Mesenchymal stem cells (MSCs) isolated from adult mice were obtained from the 
Texas A&M Health Science Center College of Medicine, Institute for Regenerative Medicine. 
MSCs were maintained as an adherent cell line in Iscove’s Modified Dulbecco’s Medium 
(IMDM; 12440-053; Invitrogen, Carlsbad, CA) containing 10%  fetal bovine serum (FBS; 
SH30071.03; Hyclone, South Logan, UT), 10% donor equine serum (SH30074; Hyclone), 2 
mM L-glutamine (25030-081; Invitrogen), and antibiotic-antimycotic solution (1%, 15240-
096; Invitrogen; 10,000 U/mL penicillin, 10,000 μg/mL streptomycin, 25 ng/mL amphotericin 
B). Cells were incubated at 37°C with 5% CO2 humidified atmosphere. When cultures reached 
75% confluence, MSCs were harvested from the flask using 0.25% trypsin and 1 mM EDTA 
solution (25200-056; Invitrogen) and were centrifuged at 500 rpm for 5 min. MSCs were 
subsequently plated into T-25 culture flasks (25 cm2) at 75-150 cells/cm2. Fresh media was 
added every other day to feed the cells. Lentiviral vectors were used to engineer MSCs to 
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produce and secrete brain-derived neurotrophic factor (BDNF; human cDNA) as well as green 
fluorescent protein (BDNF-GFP-MSCs), as previously reported (8, 36). A similar method was 
utilized to generate the GFP expressing mouse MSC line (GFP-MSCs). These cells were 
obtained from a previous study (30). 
In Vitro Transdifferentiation of MSCs  
Sub-confluent MSCs were subjected to a three-step chemical transdifferentiation 
following a previously established induction protocol (31) (modified from Dezawa et al. (35)). 
First, for 24 hours, cells were placed in Transdifferentiation Media 1 (TDM1) that consisted of 
IMDM and 1 mM β-mercaptoethanol (BME; M6250; Sigma-Aldrich, St. Louis, MO). 
Subsequently, for 72 hours, cells were placed in TDM2 that consisted of IMDM, 5% FBS, 5% 
equine serum, and 35 ng/mL all-trans retinoic acid (ATRA; R2625; Sigma-Aldrich). Finally, 
cells were placed in TDM3 for 8-20 days. TDM-3 consisted of IMDM, 5% FBS, 5% equine 
serum, 14 μM forskolin (FSK, 344270; EMD Millipore, Billerica, MA), 5 ng/mL platelet 
derived growth factor (PDGF; H8291-10UG; Sigma-Aldrich), 10 ng/mL basic fibroblast 
growth factor (rhFGF, basic; G5071; Promega, Madison, WI), and 200 ng/mL recombinant 
heregulin β1 (HRG, PF048-50UG; Calbiochem, EMD Millipore). After 8 and 20 days in vitro 
(DIV), cells were counted and plated at 2,000 cells/well in a 96 well plate (655090; Greiner 
Bio One; Monroe, NC). Immunocytochemistry was used to characterize the control, 
undifferentiated MSCs (uMSCs), and transdifferentiated MSCs (tMSCs).  
Immunocytochemistry 
Cells were allowed a total of 48 hours to re-attach and proliferate within the 96-well 
plate. After this time, all wells were rinsed twice with 0.1 M PO4 buffer and fixed for 20 
minutes with cold 4% paraformaldehyde in 0.1 M PO4 buffer. Then, cells were rinsed 3 times 
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with filtered phosphate buffered saline (PBS; BP2944100; Fisher-Scientific, Waltham, MA) 
every seven minutes. Cells were incubated in blocking solution consisting of PBS with 5% 
normal donkey serum (NDS; 017-000-001; Jackson ImmunoResearch, West Grove, PA), 0.4% 
bovine serum albumin (A9647; BSA; Sigma), and 0.2% Triton X-100 (85111; Fisher 
Scientific).  
A panel of antibodies was used for immunocytochemistry (ICC) analysis to compare uMSCs 
vs. tMSCs (Table 1).  
Table 1.  Primary antibodies used for immunolabeling of transdifferentiated MSCs 
Primary 
Antibody 
Concentration Marker Source 
Rb-α-S100 1:500 Calcium binding protein – SC 
marker 
Sigma-Aldrich 
(S2644) 
Mo- α-S100β 1:1000 Calcium binding protein – SC 
marker 
Abcam (ab11178) 
Rb-α-p75NTR 1:1000 Neurotrophin receptor – glial 
marker 
Promega (G3231) 
Mo-α-TUJ1 1:200 βIII-Tubulin – neuronal marker R & D systems 
(MAB1195) 
Rb-α-GFAP 1:200 Intermediate filament – SC 
marker 
EMD Millipore 
(MAB360) 
Rb- α-Ki67 1:200 Proliferation marker Abcam (ab16667) 
 
The primary antibodies were diluted with blocking solution and cells were incubated 
overnight at 4°C. Following incubation, cells were rinsed with PBS 4 times every 8 minutes, 
and incubated in secondary antibodies diluted in blocking solution. The following secondary 
antibodies were used: Donkey-α-Mouse Cy3 (715-165-51; Jackson ImmunoResearch Labs, 
1:500) and Donkey-α-Rabbit Cy3 (711-165-152; Jackson ImmunoResearch Labs, 1:500). Cell 
nuclei were stained with DAPI (2-(4-amidinophenyl)-1H -indole-6-carboxamidine) (D3571; 
Invitrogen, 1:2,000) and incubated at room temperature in the dark for 60-90 minutes. Cells 
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were then rinsed with PBS 3 times every 7 minutes. Controls included cells incubated without 
any primary or secondary antibodies, as well as cells with only secondary antibody applied. 
Image Analysis 
All cell imaging was performed on the ImageXpress Micro high content screening 
system (Molecular Devices, Sunnyvale, CA).  After the ICC, each 96-well plate was loaded 
into the ImageXpress MICRO and allowed to equilibrate for 20 minutes at 37° C.  Plates were 
imaged using the 20x objective and a total of 64 microscopic fields per well were taken, for a 
total of 6,144 images per wavelength, per plate.  Three wavelengths were selected for our 
experiments: Cy3 (550 nm), GFP (395 nm), and DAPI (358 nm). Images were analyzed via a 
multiwavelength cell scoring module on the MetaXpress 4.0 software (Molecular Devices). A 
threshold of intensity level above local background was set based upon the presumption that 
uMSCs would express minimum fluorescent levels of the antibody analyzed. Cells with 
fluorescence levels higher than the threshold were marked as positive.  Other parameters such 
as minimum and maximum cell width, minimum stained area, and cytoplasmic vs. nuclear 
staining were taken into account during the analysis. For a more detailed procedural 
description, please refer to Sharma et al. 2015 (31). The percentage of positively stained cells 
was calculated by dividing the number of cells immunoreactive to each antibody by the total 
number of DAPI-stained nuclei per image.  Every Cy3 and DAPI image was analyzed in order 
to calculate the average percentage of Cy3 expressing cells per well.  Subsequently, the average 
percentage of Cy3 expression was calculated according to cell type and averaged across a total 
of four 96-well plate replicates. The Tukey-Kramer Corrections or a student’s t-test test was 
used to compare means for all data analysis using R open software and GraphPad open 
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software. A p-value ≤ 0.05 was considered significant. Error bars in graphs represent the 
standard error.  
ELISA of BDNF Production 
An enzyme-linked immunosorbent assay (ELISA) was used to quantify BDNF release 
from the genetically modified MSCs (GFP-MSCs and BDNF-MSCs). The Emax Immunoassay 
was used (G7610; Promega, Madison, WI) to measure levels of BDNF in conditioned media 
from BDNF-MSCs and GFP-MSCs for 48 hours. Cells were plated at 10,000 cells per well in 
a six-well plate and allowed to grow for 48 hours. Conditioned media was collected and 
immediately frozen at -20°C.  The ELISA was performed as per the kit manufacturer’s 
instructions.  
PC12-TrkB cell neurite outgrowth assay 
PC12-TrkB cells were used to assess the bioactivity of BDNF released from MSCs. 
Rat pheochromocytoma derived PC12 cells, which were genetically modified to express the 
TrkB neurotrophin receptor, were provided by Dr. Moses Chao (Helen L. and Martin S. 
Kimmel Center for Biology and Medicine at the Skirball Institute for Biomolecular Medicine, 
New York Univ.). Cells were maintained in RPMI-1650 (ATCC Cell Biology; Manassas, VA) 
containing 10% heat inactivated equine serum (SH30074; Hyclone, South Logan, UT) and 5% 
fetal bovine serum. Cells were incubated at 37°C with 5% CO2 . To observe neurite outgrowth, 
PC12-TrkB cells were plated at 3,000 cells per well of a 96 well plate. Using the condition 
media collected from MSCs (see above), PC12 cells were grown in a 50:50 mixture of 
condition media and PC12 maintenance media (MM). Twenty ng of human recombinant 
BDNF in PC12 MM was used as a control (rhBDNF; 248-BD005; R&D systems, Minneapolis, 
MN). Cells were allowed to adhere for 48 hours and were subsequently fixed with 4% 
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paraformaldehyde in 0.1 M PO4 buffer. Neurite outgrowth was visualized with an Anti-Beta 
III tubulin Cy3 conjugated antibody (AB15708C3; EMD Millipore, Billerica, MA; 1:100).  For 
image analysis, 25 microscopic fields in each well were taken randomly using a 20x objective 
on the ImageXpress MICRO high content screening system. The MetaXpress 4.0 software’s 
neurite outgrowth module was used to calculate the average neurite length per cell (microns) 
for each condition.  
Morphometric analysis 
Changes to cell morphology were analyzed using the parameters of aspect ratio and 
total cell area. The aspect ratio is the ratio of a cell’s length (longest dimension) to its breadth 
(shortest width), and is expected to be a value of one or greater. A value of one is seen for 
objects whose length and width are the same, such as circles/regular polygons. Several studies 
demonstrate that aspect ratio of MSCs may affect their lineage commitment (31, 37). For our 
purposes, aspect ratio was used as an indicator of cellular elongation when comparing uMSCs 
and tMSCs.  
Thirty cells per condition (BDNF uMSC, BDNF tMSC, GFP uMSC, GFP tMSC) were 
analyzed. Four experimental replicates were analyzed for a total of 120 cells per condition. 
This protocol was previously established using the MetaXpress software Morphometric 
Analysis program (31). A student’s t-test test was used to compare means within the same cell 
type on GraphPad prism v6 software (GraphPad Software, Inc., La Jolla, CA). A p-value ≤ 
0.05 was considered significant. Error bars in graphs represent the standard error. 
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4. Results 
Characterization of uMSCs 
In a previous study by Sharma et al. 2015 (30), the viability and proliferation of BDNF-
GFP and GFP mouse MSCs were compared to the original population of non-genetically 
modified MSCs using a number of in vitro assays such as propidium iodide staining, Ki67 
immunolabeling, and cellular migration via time-lapse digital imaging. The results 
demonstrated no significant differences between genetically modified MSCs and unmodified 
MSCs, confirming the health of BDNF-GFP and GFP expressing MSC lines.  
Effect of Chemical Transdifferentiation on Cell Morphology 
Cells which were exposed to transdifferentiation media appeared bipolar and assumed 
a spindle cell appearance, whereas control cells exhibited a typical fibroblast-like morphology 
(Fig. S1).  This observation was analytically supported via MetaXpress morphometric analysis 
(Fig. 1). The aspect ratio, an indicator of cell elongation, was calculated to compare the 
phenotype of transdifferentiated cells to control cells. A ratio close to one indicates cells with 
a more circular shape, whereas a ratio > 1 is produced by cells with a linear, elongated 
morphology.  All four of our cell types had aspect ratios greater than 1, indicating cell length 
is greater than breadth. The aspect ratio of GFP tMSCs (4.1 ± 0.32) was significantly higher 
than uMSCs (1.8 ± 0.33), indicating that transdifferentiated cells are more elongated and have 
a bipolar morphology (Fig. 1A). BDNF tMSCs also had a higher aspect ratio of 3.4 as 
compared to uMSCs (3.07); however, the difference was not significant (Fig. 1A). Average 
total cell area was also compared between the cells grown in MM and TDM. Average cellular 
area was: BDNF uMSCs – 939.5 μm2, BDNF tMSCs – 1347.1 μm2, GFP uMSCs – 1106.6 
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μm2, and GFP tMSCs – 1192.5 μm2. While both types of tMSCs had a higher average area, 
there was no significant difference between any of the cell types (Fig. 1B). 
After 8 days growth in TDM3, a significantly larger number of BDNF tMSCs were 
positively labeled by anti-S100, anti-S100β, and anti-p75NTR. Specific staining was not seen 
for GFAP or TuJ1 for any cell type. S100 immunolabeling was identified in the cytoplasm 
with only minor staining seen in the nucleus, consistent with expected findings (Fig. S2A and 
B). Transdifferentiated BDNF cells showed approximately a six-fold higher percentage of 
S100 immunolabeling compared to uMSCs (Figure 4A): 42% ± 9.9 versus 6.9% ± 4.4, 
respectively. Anti-S100β binds to the glial specific S100β protein, and is a more exclusive 
marker than anti-S100, which is expressed by many different cell types (41) . S100β staining 
was only seen in the cytoplasm (Fig. 2A and B).  Again, BDNF tMSCs demonstrated higher 
levels of staining (29.1% ± 1.9) than uMSCs (4.7% ± 1.3), with a six-fold difference observed 
(Fig. 4A). Up to 52 ±10% of BDNF tMSCs expressed p75NTR neurotrophin receptor (Fig. 3A 
and B, and 4).  Ki67 was similar for both BDNF cell types, with approximately 25% of cells 
showing active proliferation, demonstrating results similar to those found by Sharma et al. 
2015 (30) (Fig. S3A, B). 
Transdifferentiated GFP cells showed markedly different results from the BDNF cells. 
GFP MSCs showed only a significant difference in antibody immunolabeling for S100β (Fig. 
2A).  Approximately 23.9% ± 5.2 of GFP tMSCs were immunolabeled by S100β antibody, 
while only 6.1% ± 0.5 of uMSCs showed labeling. GFP tMSCs had a higher average 
percentage of cells immunolabeled for S100 and p75NTR , but the variability between replicates 
was too great to be significant. Again, Ki67 was similar for both cell types, with 30% of cells 
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showing immunolabeling (Fig. S3C, D). In general, both GFP cell types appeared to proliferate 
more than their BDNF counterparts.  
At 20 days growth in TDM3, cells were additionally tested to assess cell proliferation 
and cell marker profiles. After 20 days growth in TDM3, BDNF cells appeared largely 
unchanged when compared to day 8 cells. BDNF tMSCs continued to express significantly 
higher levels of S100, S100β, and p75NTR (Fig. 4B). Again, immunolabeling for GFAP and 
TuJ1 was not noted for any cell type. When compared to Day 8 there was a decrease (42 vs. 
27%) in S100 immunolabeled BDNF-tMSCs on Day 20; however, levels were still 
significantly higher than BDNF uMSCs. A similar drop was noted for BDNF tMSC levels of 
p75NTR (52% on Day 8; 34% on Day 20). S100β remained consistent from Day 8 to Day 20 
for BDNF tMSCs (29% vs. 32%). The BDNF uMSCs continued to express minimum levels of 
Schwann cell markers (5-8%).  Ki67 immunolabeling demonstrated no significant difference 
between BDNF cell types and remained close to ~25% as on Day 8.   
Post 20 days TDM3, GFP cells appeared further transdifferentiated to resemble a 
Schwann cell-like phenotype. A significant difference was noted between GFP tMSCs and 
uMSCs for S100 and p75, however, no difference was seen for S100β (Fig. 4B).  GFP tMSC 
expression of S100 actually increased by approximately 10% (20% on Day 8; 30% on Day 
20).  The opposite effect was noted for p75 expression, with a drop in expression of 10%.  
Again, Ki67 levels remained at roughly 25-30%.  
Combined, the ICC results demonstrate that both GFP and BDNF MSCs assumed a 
Schwann cell-like phenotype, based off the increased immunolabeling for specific markers. In 
general, BDNF cells showed a significant change in their immunolabeling profile faster than 
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GFP cells, and at higher levels. Both cell types retained their SC-like phenotype for up to 20 
days in TDM3.  
Quantification of BDNF Production from MSCs 
ELISAs were performed using conditioned media samples, to quantitatively determine 
BDNF levels.  After 8 days growth in TDM3, BDNF cells were secreting significantly higher 
levels of the neurotrophic factor than the GFP control cells. Secretion of BDNF from control 
GFP uMSCs was 2.74 ± 2.7 ng/mL/ million cells/day. Levels of BDNF were undetectable from 
the conditioned media collected from the GFP tMSCs (Fig. 6A).  BDNF uMSCs and tMSCs 
secreted significantly higher amounts of BDNF than both GFP cell types (45.16 ± 14.0 and 
39.8 ± 6.3 ng/mL/ million cells/day, respectively). A Tukey-Kramer test revealed significant 
differences between both BDNF cell types and GFP cells. There was no significant difference 
between BDNF uMSCs and tMSCs.  
ELISAs conducted after 20 days growth in TDM3 revealed continued BDNF 
production and secretion by the BDNF uMSCs (71.32 ± 17.78 ng/mL/million cells/day) and 
BDNF tMSCs (102.26 ± 30.37 ng/mL/million cells/day) (Fig. 6A). Again, there was no 
significant difference between BDNF cell types. There was no significant difference in BDNF 
levels between 8 vs. 20 days in TDM3. GFP uMSCs and tMSCs appeared to be producing 
similar levels of BDNF, approximately 16.9 ng/mL/million cells/day.  A Tukey-Kramer test 
revealed significant differences between BDNF tMSCs and both GFP cell types.  A student’s 
t-test calculated a significant p-value of 0.04 for the difference between BDNF uMSCs and 
GFP tMSCs. The difference between BDNF uMSCs and GFP uMSCs was very close to 
statistical significance, with a p-value of 0.054. These results demonstrated that the 
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transdifferentiation process did not alter the ability of the BDNF MSCs to produce and secrete 
significant quantities of BDNF.  
BDNF Bioactivity: PC12-TrkB neurite outgrowth assay 
The PC12-TrkB cell assay was utilized in order to assess the bioactivity of secreted 
BDNF. The original PC12 cells are a clonal cell line derived from a rat pheochromocytoma, 
which project long neurites when exposed to NGF (42) . The PC12-TrkB cells were genetically 
programmed to over-express the BDNF neurotrophin receptor, TrkB (43). By comparing 
neurite length between conditions, PC12-TrkB cells were used to assess the bioactivity of MSC 
secreted BDNF. Immunolabeling for TuJ1 showed the extent of neurite outgrowth for PC12-
TrkB cells cultured in the following conditioned medias: GFP uMSC (Fig. 5), GFP tMSC (B), 
PC12 growth media (C) BDNF uMSC (D), BDNF tMSC (E), and 20 ng rhBDNF control.  
Eight-day conditioned media from both BDNF uMSCs and tMSCs visibly enhanced PC12-
TrkB neurite outgrowth when compared to GFP conditioned media (Fig. 6B), with an average 
neurite outgrowth of 50.0 ± 1.8 μm and 41.6 ± 6.0 respectively, vs. 4.4 ± 0.4 and 5.5 ± 1.4 μm 
for GFP MSCs. No statistical difference was found between both BDNF cell conditioned 
medias and the rhBDNF positive control (data not shown). Similarly, there was no significant 
difference between both GFP cell conditioned medias and the negative control (data not 
shown).  Very similar results were confirmed for the conditioned media collected after 20 days 
in TDM3   (Fig. 6B).  The neurite outgrowth for BDNF uMSCs vs. tMSCs was 43.7 ± 4.2 μm 
and 54.3 ± 7.3 respectively, vs. 5.0 ± 1.1 and 8.5 ± 1.9 μm for GFP MSCs. Together these 
results demonstrate that BDNF MSCs (both uMSCs and tMSCs) are capable of producing and 
secreting bioactive BDNF with potent neurite outgrowth promoting activity. 
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5. Discussion 
Peripheral nerve injury limits mobility and sensation in up to 2.8% of trauma patients 
and often results in unsatisfactory return to function (9, 44). The gold standard for severe 
transected peripheral nerve damage involves microsurgery replacement with an autologous 
nerve graft. However, due to donor site morbidity, many studies have shifted focus to glial cell 
transplants. Schwann cells are the primary glial cells of the peripheral nervous system and are 
necessary for nerve damage repair and regeneration. Specifically, SCs remove myelin debris 
and guide the directed growth of regenerating axons by undergoing dedifferentiation, 
proliferation, and migration (45, 46). Additionally, SCs produce neurotrophic factors such as 
BDNF, NGF, NT-3, and NT-4/5, which are necessary for neuronal growth and survival (47).  
Unfortunately, SCs can only be obtained by sacrificing a healthy nerve, and the process of cell 
culture is often arduous (48). In search of an alternative to Schwann cells, many studies have 
looked at mesenchymal stem cells, especially the process of transdifferentiation into a 
Schwann cell-like phenotype (38, 39, 40). For our purposes, we chose to study MSCs not only 
for their plasticity, but also because of our past success in genetically modifying these cells as 
delivery vehicles to hypersecrete neurotrophic factors (8, 30, 36). Since neurotrophic factors 
such as BDNF promote nerve regeneration, they hold great therapeutic potential. Current 
clinical use of BDNF is limited, however, due to absence of safe and reliable delivery systems 
that can provide sustainable effective concentrations over time (49). As an alternative to 
traditional nerve regeneration therapies, we combined dual strategies to investigate the 
transdifferentiation of BDNF hypersecreting MSCs into an SC-like phenotype.  
In the current study, we subjected both BDNF and GFP expressing mouse MSCs to a 
transdifferentiation protocol and subsequently analyzed their morphology and SC 
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immunolabeling profile. Upon exposure to transdifferentiation media, cells became elongated 
and spindle shaped, with tMSCs demonstrating a larger on average aspect ratio. Several other 
studies have found similar morphological changes (31, 33, 35). Furthermore, 
transdifferentiated cells had higher average cellular areas than uMSCs, though no significant 
differences were observed.  
Cells were further characterized by immunostaining using Schwann cell markers such 
as S100, S100β, p75NTR, GFAP, and TuJ1. 30-50% of BDNF tMSCs were preferentially 
immunolabeled for Schwann cell markers such as S100, S100β, and p75NTR after 8 days in 
TDM3, and even out to 20 days in TDM3, with minimal decreases in expression seen. Zaminy 
et al. (50) and Ladak et al. (51) reported ~ 50% S100β expression levels and 75%  p75NTR 
levels after 6 days in TDM. However, their studies were performed on rat MSCs. Additionally, 
our cells have the added metabolic stress of expressing GFP and/or producing BDNF, and that 
might lead to lower transdifferentiation levels. No specific staining for GFAP and TuJ1 was 
noted, which is consistent with our previous results (31).  
After 8 days in TDM3, GFP tMSCs only showed significant immunolabeling for 
S100β, but after 20 days in vitro, cells showed significantly higher levels for both S100 and 
p75NTR. These findings suggest that BDNF itself may facilitate conversion of cells to an SC-
like phenotype faster. Several studies, in fact, reported mouse and human MSC 
transdifferentiation protocols, which rely on BDNF, among several agents (41, 52). 
Furthermore, a recent publication by (53) found that secreted BDNF can influence phenotype 
modulations of SCs and neurons, forming a positive feedback for nerve development and 
regeneration , leading us to believe that exposure to BDNF may convert cells to an SC-like 
phenotype faster.  
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After exposure to TDM conditions, BDNF production was quantified by ELISA, and 
its biological activity tested via the PC12-TrkB bioassay. The ELISA results showed that 
BDNF production was well above the GFP baseline both after 8 and 20 days in TDM3. In a 
previous study on a different BDNF MSC cell line, Harper et al. (2011) (8) found that unaltered 
BDNF MSCs secrete approximately 41 ng BDNF/million cells/day. This is very similar to our 
findings of 45.2 and 39.8 ng/mL/ million cells/day after 8 days in TDM3. These results are 
very promising, given that Harper’s results were obtained from unaltered cells, signifying that 
the process of transdifferentiation does not repress BDNF secretion. The bioactivity of secreted 
BDNF was verified by the increased neurite outgrowth of PC12-TrkB cells. These findings 
suggest that not only is BDNF actively secreted by our cells, but also that it has the capacity to 
promote neurite sprouting and regeneration. Were these cells to be used for in vivo studies, we 
believe they could increase axonal outgrowth and survival. Given the fact that BDNF 
production remained stable for over 20 days, we believe these cells have the capacity to 
produce sustainable, effective BDNF concentrations over prolonged time periods.  
Our research group has previously shown that lentiviral induced BDNF MSCs have the 
capacity to survive and protect neuronal function within the retina (8) . For future studies, we 
hope to transplant BDNF tMSCs within a biodegradable conduit into a rat sciatic nerve gap 
model in order to assess the in vivo effects on peripheral nerve regeneration.  In addition to 
peripheral nerve transections, BDNF hyper-secreting MSCs could be used in the treatment of 
spinal cord trauma (54), ischemic stroke (55), Parkinson’s (56), and many other 
neurodegenerative disorders. We hope our results from this study encourage the future use of 
transdifferentiated genetically modified MSCs as a reliable and effective system for delivery 
of neurotrophic or other therapeutic factors.  
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6. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The aspect ratios and cellular areas of undifferentiated versus transdifferentiated 
MSCs. (A) Aspect ratio of GFP and BDNF cells. Aspect ratio is the ratio of length vs. 
breadth of the cell. A ratio greater than one implies cellular elongation. GFP tMSCs had an 
aspect ratio significantly greater than GFP uMSCs, implying a greater average cell length. 
(B) Average total cellular area of GFP and BDNF MSCs. There were no significant 
differences between cell types. Error bars represent standard error of the mean. N = 30 cells 
per condition, four independent transdifferentiation experiments carried out.  Total of 120 
cells per condition. *Significantly different at p ≤0.05. 
68 
 
Figure 2. Anti-S100β immunolabeled BDNF and GFP uMSCs vs. tMSCs at 8 days in TDM3. 
(A) BDNF uMSCs (B) BDNF tMSCs (C) GFP uMSCs (D) GFP tMSCs.  BDNF tMSCs 
expressed a significantly higher percentage of Cy3 immunostaining for S100β when compared 
to BDNF uMSCs.  A greater percentage of GFP tMSCs immunolabeled for S100β after 8 days 
in TDM3 but not after 20 days TDM3. All cells immunolabeled for S100β in the cytoplasm. 
Calibration bar represents 100 μm. 
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Figure 3. Anti- p75NTR immunolabeled BDNF and GFP uMSCs vs. tMSCs. Minimal 
immunolabeling for p75NTR was observed in the BDNF uMSCs (A) or the GFP uMSCs (C). 
(B) In comparison, 50% of BDNF tMSCs immunolabeled specifically for p75NTR. (D) 
Similarly, a significantly higher percentage of GFP tMSCs were immunolabeled for p75NTR 
after 20 days in TDM3 but did not after only 8 days in TDM3. Cells showed immunostaining 
for p75NTR in the nucleus and cytoplasm. Calibration bar represents 100 μm. 
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Figure 4. Immunolabeling characterization of BDNF and GFP uMSCs vs. tMSCs: 
S100, S100β, p75NTR, and Ki67 labeled cells. Specific staining for GFAP and TuJ1 
were never noted and are thus not included in this data. (A) Immunolabeling for GFP 
and BDNF MSCs after 8 days growth in TDM3. S100, S100β, and p75NTR staining was 
significantly higher in BDNF tMSCs than the uMSCs (p ≤0.05). In GFP cells, S100β 
immunostaining was significantly higher in tMSCs than uMSCs (p ≤0.05). Ki67 was 
not significantly different between any cell types. (B) Immunostaining results for GFP 
and BDNF MSCs after 20 days growth in TDM3. Again, S100, S100β, and p75NTR 
staining was significantly higher in BDNF tMSCs (p ≤0.05) than the uMSCs. GFP cells 
demonstrated a large shift in their immunolabeling profile, with a significantly larger 
percentage of GFP tMSCs staining positive for S100 and p75NTR. Again, no significant 
differences were noted between cell types for the Ki67 marker. Error bars represent 
standard error of the mean. N = 4 independent transdifferentiation experiments carried 
out.  *Significantly different at p ≤0.05. ** Significantly different at p ≤0.01. *** 
Significantly different at p ≤0.001 
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Figure 5.  PC12-TrkB neurite outgrowth under several media conditions. Fluorescence images 
of TuJ1 immunolabeling to detect neurite outgrowth. (A) PC12-TrkB cells grown in GFP 
uMSC condition media. Cells remained spherical with few detectable neurites. (B) Cells grown 
in GFP tMSC condition media. No neurite outgrowth was observed. (C) Negative control. Few 
neurites were observed when PC12-TrkB cells were grown in their own maintenance media -
RPMI-1640. (D) PC12-TrkB cells in BDNF uMSC condition media. Cells flattened and often 
produced several long neurites. (E) Cells in BDNF tMSC condition media. Similar results to 
(D).  (F) Positive control. Cells were grown in the presence of 20 ng rhBDNF and again long 
neurites were seen, similar to (D) and (E).  Scale bar represents 100 μm.  
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Figure 6. Estimation of BDNF secreted and assessment of its bioactivity. (A) BDNF 
secretion from BDNF and GFP, uMSCs and tMSCs was measured using ELISA. Lighter bars 
shows day 8 data and darker bars show day 20 data of BDNF secretion. Day 8-ELISA analysis 
revealed BDNF uMSCs secrete 45.16 ± 14.0 ng/mL/million cells/day and tMSCs secrete 
similar levels: 39.8 ± 6.3 ng/mL/ million cells/day. After 20 days, both BDNF cell types 
continued to secrete similar levels of the factor: 71.33 ± 17.8 ng/mL/ million cells/day for 
uMSCs and 102.3 ± 30.37 for tMSCs. From day 8 to day 20, a relatively higher increase in 
BDNF secretion was observed from BDNF tMSCs as compared to BDNF uMSCs indicating 
cells secrete higher amount of BDNF as number of transdifferentiation day’s increase. 
However, no significant differences were observed at p≤0.05 among BDNF cell types. GFP 
cell types secreted a significantly lower amount of BDNF at both day 8 and day 20. Error bars 
represent standard error of the mean. N = 3 independent transdifferentiation experiments. * 
represents significant differences at p≤0.05. (B) Quantification of neurite outgrowth using high 
throughput imaging system and automated analysis. Average neurite outgrowth (µm) for 
PC12-TrkB cells cultured in a variety of conditioned media. PC12-TrkB cells subjected to both 
BDNF cell type conditioned media grew significantly longer neurites compared to both GFP 
uMSC and tMSC conditioned media (p ≤0.0001) at day 8 (Lighter bars) and 20 (Darker bars). 
Day 20 BDNF tMSCs showed an increase in neurite outgrowth as compared to BDNF uMSCs 
but Neurite outgrowth was not significantly different between cells grown in BDNF tMSC vs. 
uMSC-conditioned media for either Day 8 or 20no significant differences were observed at 
p≤0.05. Extensive neurite outgrowth across all four BDNF cell type condition implies that 
BDNF threshold required for differentiation of PC12-TrkB cells is very low and using 
conditioned media from smaller number of BDNF cells might help in detecting the differences 
in neurite outgrowth. Error bars represent standard error of the mean. N = 4 independent PC12 
conditioned media experiments carried out.  * represents significant differences at p≤0.05 
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7. Supplemental material 
 
Supplemental Figure S1. Morphology of mouse mesenchymal stem cells (A) BDNF uMSCs 
in maintenance media, B) BDNF tMSCs, 6 days growth in TDM3, C) GFP uMSCs in MM, D) 
GFP tMSCs, 5 days growth in TDM3. Cells subjected to transdifferentiation media became 
more elongated and spindle-shaped compared to their control counterparts.  
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Supplemental Figure S2. Anti-S100 immunolabeled BDNF and GFP uMSCs vs. tMSCs. (A) 
BDNF uMSCs demonstrate minimal S100 staining. (B) In comparison, 40% of BDNF tMSCs 
immunolabeled specifically for S100. (C) Similar to BDNF cells, GFP uMSCs showed 
minimum labeling for S100. (D). GFP tMSCs expressed significantly higher levels of S100 
after 20 days in TDM3 but did not after only 8 days in TDM3. All cells immunolabeled for 
S100 in the cytoplasm. Calibration bar represents 100 μm.   
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Supplemental Figure S3. Anti-Ki67 immunolabeled BDNF and GFP uMSCs vs. tMSCs. (A) 
BDNF uMSCs, (B) BDNF tMSCs, (C) GFP uMSCs, and (D) GFP tMSCs.  No significant 
differences in Ki67 immunolabeling was found between any cell types, suggesting that 
transdifferentiation did not affect cell proliferation in any significant fashion.  All cells 
demonstrated nuclear staining. Calibration bar represents 100 μm.   
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CHAPTER 4 
CONCLUSION 
The bulk of our study contributes toward the in vitro characterization of a new cell line 
– chemically transdifferentiated, genetically modified MSCs, made to resemble Schwann cells. 
The first step of the project was to grow cells in a series of transdifferentiation medias and then 
test for morphological as well as cell surface marker differences via immunocytochemistry. 
This part of the project was successful as BDNF tMSCs preferentially immunolabeled for 
Schwann cell markers such as S100, S100β, and p75NTR.  Initially, cells were grown in 
transdifferentiation media for a total of 12 days. This brief timeline gives our particular 
transdifferentiation protocol an advantage over some of the newer, more labor-intensive 
protocols, which may take double this amount of time (1,2). Studies indicate that ideal time for 
neural stem cell transplant is approximately one week after nerve injury (3), which would make 
our protocol a more clinically feasible option.  
In addition to being grown for 12 days, cells were also kept in transdifferentiation 
media for a total of 32 days. Several studies have demonstrated that long-term culture can alter 
genetic composition of MSCs (4,5), and cause changes in proliferation and expression patterns 
in surface markers (6). We kept cells in media for 32 days in order to observe the long-term 
effects of transdifferentiation media on MSC replication rates, and ability to express Schwann 
cell markers. Immunocytochemistry for Ki67 revealed no drastic changes in replication rates, 
and Schwann cell marker expression were very similar for 12 vs. 32 days in media. These 
results indicate that the transdifferentiation media itself does not cause alterations in 
proliferation and cell surface markers. However, to assess genomic stability and mutation rates, 
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a more complete genetic panel using methods such as SNP genotyping would be necessary, 
and would be highly recommended for moving forward with transplantation studies.  
The second part of our project was to quantify BDNF production via ELISA and 
demonstrate its bioefficacy via PC-12 cell assay. BDNF MSCs, both transdifferentiated and 
non, produced significantly higher levels of BDNF than the GFP MSCs.  Not only was BDNF 
secreted, but it was biologically active, as the PC-12 cells showed significant neurite outgrowth 
when grown in the presence of BDNF conditioned media vs. GFP MSC media. These results 
demonstrate that genetically modified cells continued to over produce BDNF, even after being 
in transdifferentiation media for both 12 and 32 days.  
While these results are very promising, our BNDF tMSCs have yet to be tested for 
ability to myelinate cells. As a next step, tMSCs could be co-cultured with dorsal root ganglion 
cells to see if tMSCs would be capable of wrapping around these cells and forming a myelin-
like structure. Additionally, patch clamp voltage testing could be used to determine whether 
these cells can act like voltage gated Schwann cells.  To further characterize changes caused 
by transdifferentiation, genomic testing should be performed on uMSCs vs. tMSCs, to 
determine what genes may be changing in response to transdifferentiation media, and what 
roles these genes may play in cell physiology and morphology.  
Since we have effectively shown that our cells can transdifferentiate and still produce 
significant quantities of BDNF, future experiments should consider seeding this cell line into 
a bioengineered conduit, and transplanting these cells into a transected sciatic nerve model. 
Important questions to consider include: Can these cells survive and remain within the conduit? 
Will the cells continue to secrete BDNF in vivo? Once no longer exposed to transdifferentiation 
media, will these cells revert back to their original MSC phenotype or will they continue to 
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express Schwann cell markers? After transplant, will the tMSCs continue to support neurite 
outgrowth and will rats functionally improve more rapidly with the addition of BDNF tMSCs? 
All of these questions are essential in determining whether or not our BDNF tMSCs could have 
any future relevant clinical applications.  
The goal of this Master’s project was to describe a novel protocol, demonstrating that 
genetically modified MSCs could still be transdifferentiated and assume a dual role in nerve 
regeneration by hyper-secreting BDNF and assuming a Schwann cell-like morphology. We 
have successfully supported the conclusion that BDNF tMSCs preferentially express Schwann 
cell markers and promote neurite outgrowth. While our research has established the 
foundations of a promising new cell line, many more questions have yet to be answered and 
further data will dictate the role of BDNF tMSCs in peripheral nerve regeneration.  
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